Serum antibodies to microbial antigens for Crohn’s disease progression
Authors:
- Gou-Zhen WangGWGou-Zhen Wang
- Jie-Qiong ZhouJZJie-Qiong Zhou
- Bing-Qing XiaBXBing-Qing Xia
- Xin-Ying WangXWXin-Ying Wang
- Bo JiangBJBo Jiang
- 1 July 2014
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 26 (7) , 733-742
Abstract
This meta-analysis evaluated the stratification powers of four well-studied serum antibodies to microbial antigens [ASCA (anti-Saccharomyces cerevisiae), anti-OmpC (anti-outer-membrane protein C), anti-I2 (anti-Pseudomonas fluorescens-associated sequence I2), and anti-CBir1 (anti-bacterial flagellin)] in characterizing progression of Crohn's disease (CD). Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) with 95% confidence intervals (CI) for individual antibodies and antibody combination were used to evaluate and compare their stratification powers for CD-related complications and the need for surgery. Eleven studies were included in this meta-analysis. In terms of the outcomes for CD complication and surgery, ASCA had the highest sensitivities at 0.66 (CI 0.63-0.69) for complications and 0.66 (CI 0.63-0.68) for surgery, whereas anti-OmpC had the highest specificities at 0.83 (CI 0.80-0.85) for complications and 0.81 (CI 0.79-0.83) for surgery. Anti-OmpC had the highest DORs at 2.61 (CI 2.16-3.15) for complications and 2.93 (CI 2.48-3.47) for surgery, and a combination of at least two antibodies presented pooled DORs at 2.93 (CI 2.42-3.56) for complications and 3.39 (CI 2.73-4.20) for surgery, superior to any single antibody. Anti-OmpC had the highest stratification power among the four antibodies screened for the risk of both complications and surgery in CD patients, and the power became stronger when antibodies were assessed in combination.Keywords
This publication has 25 references indexed in Scilit:
- Clinical factors predictive of Crohn’s disease complications and surgeryEuropean Journal of Gastroenterology & Hepatology, 2013
- Current and future role of biomarkers in Crohn's disease risk assessment and treatmentClinical and Experimental Gastroenterology, 2011
- The Prognostic Power of the NOD2 Genotype for Complicated Crohn's Disease: A Meta-AnalysisAmerican Journal of Gastroenterology, 2011
- Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's diseaseGut, 2011
- Positioning biologic agents in the treatment of Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Review article: the burden of hepatic encephalopathyAlimentary Pharmacology & Therapeutics, 2007
- Anti-Glycan Antibodies as Biomarkers for Diagnosis and PrognosisLupus, 2006
- Predictors of Crohn’s DiseaseGastroenterology, 2006
- Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgeryGut, 2005
- The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based studyGastroenterology, 2001